慈丹胶囊联合TACE治疗原发性肝癌临床效果的系统评价

目的：系统评价慈丹胶囊联合经肝动脉化疗栓塞（TACE）治疗原发性肝癌的临床效果。方法：计算机检索万方数据库、维普中文科技期刊数据库、中国生物医学文献数据库、中国知网、Pubmed数据库、EMbase、Cochrane图书馆，收集有关慈丹胶囊联合经肝动脉化疗栓塞治疗原发性肝癌的随机对照试验文献，两位研究者单独评价纳入研究的方法学质量并提取资料，应用Revman5.3软件对符合条件的文献进行Meta分析。结果：纳入RCT文献7篇，涉及1 183例患者。Meta分析结果显示，与单独应用TACE比较，慈丹胶囊联合TACE在肝癌的近期疗效方面具有优势，差异有统计学意义（RR=1.70，95% CI：1.50～1.93，P<0.01）；对于提高患者1年生存率同样具有优势，差异有统计学意义（RR=1.80，95% CI：1.43～2.27，P<0.01）。结论：慈丹胶囊联合TACE能够改善患者近期疗效，提高患者生存率，但对于生活质量的改善与降低毒副反应两方面尚需大量高质量的RCTs进一步证实。

Systematic review of clinical effects of Cidan capsules combined with TACE in treatment against primary liver cancer

OBJECTIVE To assess clinical effects of Cidan capsules combined with TACE in treatment against primary liver cancer.METHODS Randomized controlled trials (RCTs) of Cidan capsules combined with TACE in patients with primary liver cancer were searched in Wan Fang database, VIP database, Chinese biomedicine literature database, CNKI database, Pubmed, EMbase and Cochrane Library. Two reviewers independently assessed quality of included studies and extracted data. Selected literatures were evaluated by Revman 5.3 and Meta-analysis was conducted.RESULTS Seven RCTs were selected, involving 1 183 cases of patients. Meta-analysis showed that there were significant differences between experimental groups (Cidan capsules+TACE) and control groups (TACE) in raising short-term effects (RR=1.70, 95% CI:1.50-1.93, P<0.01) and increasing one-year survival rate (RR=1.80, 95% CI:1.43-2.27, P<0.01).CONCLUSION Cidan capsules combined with TACE in treatment against primary liver cancer can improve short-term effects and increase one-year survival rate. RCTs of high quality and large sample sizes are still needed to confirm whether such combination can improve living quality and reduce side effects.